COPD Co-infection With Tuberculosis on Th17 Cell Differentiation

Sponsor
Peking University Third Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04966052
Collaborator
Beijing Geriatric Hospital (Other)
80
1
26
3.1

Study Details

Study Description

Brief Summary

This project will observe and follow up the changes of pulmonary function and CT in patients with smoking combined with pulmonary tuberculosis, and measure the ratio of Th1 cells, Th17 cells, macrophages and neutrophils and the secretion of factors such as TNF-α, IFN-γ and IL-17 in pulmonary blood and alveolar lavage fluid.

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Detailed Description

Chronic obstructive pulmonary disease (COPD) and tuberculosis are major global health problems, and acquired and acquired immunity play an important role in COPD and tuberculosis, and there is an interaction between COPD and tuberculosis, but the exact mechanism is not clear. Pre-existing TB infection is an independent risk factor for COPD and can aggravate pulmonary function and increase hospitalization and mortality in COPD patients. In COPD patients, Th1 and Th17 cells are involved in the development of COPD and emphysema through activation of macrophages and recruitment of neutrophils, while matrix metalloproteinases (MMPs) of macrophage and neutrophil origin are involved in the formation of tuberculosis cavities, and cytokines such as TNF-α, IFN-γ, IL-17 are involved in the mechanism of their destruction, IL-17 restricts the expression of HIF-1α to inhibit the development of TB granulomas, and CT analysis revealed that combined TB exacerbates emphysema in COPD patients. The above evidence suggests that tuberculosis plays an important role in the formation of emphysema in COPD. In this project, we will observe and follow up the changes of pulmonary function and CT in patients with smoking combined with pulmonary tuberculosis, and examine the ratio of Th1 cells, Th17 cells, macrophages and neutrophils and the secretion of TNF-α, IFN-γ, and IL-17 in pulmonary blood and alveolar lavage fluid.

Study Design

Study Type:
Observational
Actual Enrollment :
80 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Effect of COPD Co-infection With Tuberculosis on Th17 Cell Differentiation and Its Significance
Actual Study Start Date :
Apr 1, 2018
Actual Primary Completion Date :
Apr 1, 2020
Actual Study Completion Date :
Jun 1, 2020

Arms and Interventions

Arm Intervention/Treatment
COPD combined with TB group

COPD combined with pulmonary TB infection

Other: No intervention
No intervention

COPD non-TB control group

COPD combined without pulmonary TB infection

TB non-COPD control group

pulmonary TB infection without COPD

Non-smoking non-TB control group

Non-smoking without pulmonary TB infection

Outcome Measures

Primary Outcome Measures

  1. Differentiation of Th17 cells [Day 1]

    Distribution of T cell subtypes, including CD4+, CD8+ T cells and Th17 cells, in blood specimens and alveolar lavage fluid by flow cytometry

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Clinical diagnosis of COPD

  • age ≧ 40

Exclusion Criteria:
  • Presence of other chronic respiratory diseases other than COPD, such as asthma, bronchiectasis, interstitial lung disease, etc.

  • History of chest and lung surgery.

  • History of malignancy.

  • Autoimmune disease.

  • Long-term oral glucocorticoids, immunosuppressants and inhaled glucocorticoids.

  • Mental abnormalities, cognitive impairment, inability to cooperate with pulmonary function and other tests.

  • Acute stage of infection, such as lung infection, urinary tract infection and gastrointestinal tract infection, etc.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking University Third Hospital Beijing Beijing China 100191

Sponsors and Collaborators

  • Peking University Third Hospital
  • Beijing Geriatric Hospital

Investigators

  • Principal Investigator: Yongchang Sun, MD, Peking University 3rd Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking University Third Hospital
ClinicalTrials.gov Identifier:
NCT04966052
Other Study ID Numbers:
  • M2017390
First Posted:
Jul 19, 2021
Last Update Posted:
Jul 19, 2021
Last Verified:
Jul 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 19, 2021